Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study

INTRODUCTION: SARS-CoV-2 replication in cell cultures has been shown to be inhibited by ivermectin. However, ivermectin's low aqueous solubility and bioavailability hinders its application in COVID-19 treatment. Also, it has been suggested that best outcomes for this medication can be achieved...

Descripción completa

Detalles Bibliográficos
Autores principales: M. Mansour, Suzan, N. Shamma, Rehab, A. Ahmed, Kawkab, A. Sabry, Nirmeen, Esmat, Gamal, A. Mahmoud, Azza, Maged, Amr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299187/
https://www.ncbi.nlm.nih.gov/pubmed/34333358
http://dx.doi.org/10.1016/j.intimp.2021.108004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299187/
https://www.ncbi.nlm.nih.gov/pubmed/34333358
http://dx.doi.org/10.1016/j.intimp.2021.108004

Ejemplares similares